This report was first published by Endpoints News. To see the original version, click here
The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday.
The patient who died had “grade 4 neutropenia and concurrent septic shock,” the company said in a press release. The other three grade 4 incidents included two cases of thrombocytopenia and one case of myocarditis, a type of heart inflammation.
您已阅读27%（543字），剩余73%（1435字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。